CAREDX, INC. (CDNA) Operating Margin
- Operating margin · 12 months: Value 23.61%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 23.61% | Operating income / revenue. Period ending 2026-06-30. $108.14M ÷ $458.09M × 100 ≈ 23.61% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 108.14M USD | Operating Income (Loss) |
| Revenue | 458.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 79.87M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $108.14M | $458.09M | (m) | $79.87M | (m) | 23.61% |
| 2026-03-31 | $-16.21M | $412.82M | (m) | $74.32M | (m) | -3.93% |
| 2025-12-31 | $-30.78M | $379.81M | (m) | $71.43M | (m) | -8.10% |
| 2025-09-30 | $59.64M | $358.00M | (m) | $68.64M | (m) | 16.66% |
| 2025-06-30 | $46.16M | $340.83M | (m) | $69.36M | (m) | 13.54% |
| 2025-03-31 | $49.96M | $346.42M | (m) | $72.22M | (m) | 14.42% |
| 2024-12-31 | $40.77M | $333.79M | (m) | $72.41M | (m) | 12.21% |
| 2024-09-30 | $-156.56M | $312.77M | (m) | $74.15M | (m) | -50.05% |
| 2024-06-30 | $-174.85M | $297.08M | (m) | $75.67M | (m) | -58.86% |
| 2024-03-31 | $-198.38M | $275.11M | (m) | $76.22M | (m) | -72.11% |
| 2023-12-31 | $-203.36M | $280.32M | (m) | $81.87M | (m) | -72.55% |
| 2023-09-30 | $-99.85M | $297.14M | (m) | $87.16M | (m) | -33.60% |
| 2023-06-30 | $-88.41M | $309.31M | (m) | $90.47M | (m) | -28.58% |
| 2023-03-31 | $-82.50M | $319.64M | (m) | $92.86M | (m) | -25.81% |
| 2022-12-31 | $-77.23M | $321.79M | (m) | $90.39M | (m) | -24.00% |
| 2022-09-30 | $-73.51M | $318.63M | (m) | $88.86M | (m) | -23.07% |
| 2022-06-30 | $-64.90M | $314.86M | (m) | $86.00M | (m) | -20.61% |
| 2022-03-31 | $-47.92M | $308.41M | (m) | $82.40M | (m) | -15.54% |
| 2021-12-31 | $-29.73M | $296.40M | (m) | $76.53M | (m) | -10.03% |
| 2021-09-30 | $-17.39M | $275.82M | (m) | $67.80M | (m) | -6.31% |
| 2021-06-30 | $-11.57M | $253.60M | (m) | $60.84M | (m) | -4.56% |
| 2021-03-31 | $-17.64M | $221.21M | (m) | $54.93M | (m) | -7.97% |
| 2020-12-31 | $-22.53M | $192.19M | (m) | $48.94M | (m) | -11.72% |
| 2020-09-30 | $-25.01M | $169.37M | (m) | $44.56M | (m) | -14.76% |
| 2020-06-30 | $-28.85M | $149.81M | (m) | $40.61M | (m) | -19.25% |
| 2020-03-31 | $-24.89M | $139.47M | (m) | $35.11M | (m) | -17.84% |
| 2019-12-31 | $-24.53M | $127.07M | (m) | $30.71M | (m) | -19.31% |
| 2019-09-30 | $-21.40M | $114.76M | (m) | $25.55M | (m) | -18.65% |
| 2019-06-30 | $-17.37M | $102.13M | (m) | $20.89M | (m) | -17.01% |
| 2019-03-31 | $-15.74M | $88.50M | (m) | $16.76M | (m) | -17.78% |
| 2018-12-31 | $-15.58M | $76.57M | (m) | $14.51M | (m) | -20.35% |
| 2018-09-30 | $-17.45M | $65.56M | (m) | $13.76M | (m) | -26.62% |
| 2018-06-30 | $-18.59M | $56.57M | (m) | $12.85M | (m) | -32.87% |
| 2018-03-31 | $-16.98M | $50.79M | (m) | $12.47M | (m) | -33.44% |
| 2017-12-31 | $-20.29M | $48.32M | (m) | $12.39M | (m) | -42.00% |
| 2017-09-30 | $-34.87M | $46.68M | (m) | $12.51M | (m) | -74.69% |
| 2017-06-30 | $-35.94M | $46.96M | (m) | $12.48M | (m) | -76.52% |
| 2017-03-31 | $-39.31M | $45.65M | (m) | $12.51M | (m) | -86.10% |
| 2016-12-31 | $-37.33M | $40.63M | (m) | $12.38M | (m) | -91.88% |
| 2016-09-30 | $-22.93M | $36.42M | (m) | $11.94M | (m) | -62.97% |
| 2016-06-30 | $-21.19M | $31.10M | (m) | $11.70M | (m) | -68.15% |
| 2016-03-31 | $-17.11M | $27.49M | (m) | $11.07M | (m) | -62.24% |
| 2015-12-31 | $-11.93M | $28.14M | (m) | $9.33M | (m) | -42.40% |
| 2015-09-30 | $-7.04M | $29.45M | (m) | $7.93M | (m) | -23.91% |
| 2015-06-30 | $-2.46M | $28.95M | (m) | $6.26M | (m) | -8.48% |
| 2015-03-31 | $86.00K | $28.60M | (m) | $4.55M | (m) | 0.30% |
| 2014-12-31 | $1.25M | $27.31M | (m) | $3.85M | (m) | 4.58% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $23.04M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-857.00K | $22.10M | (m) | $3.18M | (m) | -3.88% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-2.34M | $20.45M | (m) | $4.75M | (m) | -11.45% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |